---
schema_version: "secwatch.filing_event.v1"
accession: "0001730430-26-000029"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2026-05-29T20:35:27+00:00"
generated_at: "2026-05-29T20:36:59.359555+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Kiniksa shareholders re-elect all three Class II directors and approve all eight proposals at 2026 annual meeting

## Summary
- Stephen R. Biggar re-elected with 37.5M for, 12.0M against; G. Bradley Cole and Barry D. Quart each received ~48.3M for.
- PricewaterhouseCoopers LLP approved as both UK statutory auditor and US independent auditor with overwhelming votes.
- Advisory vote on named executive officer compensation passed with 48.1M for and 1.3M against.
- All eight proposals, including director elections, auditor appointments, and remuneration reports, were duly passed.

## SEC filing metadata
- accession: 0001730430-26-000029
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2026-05-29T20:35:27+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000173043026000029/0001730430-26-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000173043026000029/knsa-20260529x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730430-26-000029
- JSON: https://secwatch.observer/filing/0001730430-26-000029.json
- Plain text: https://secwatch.observer/filing/0001730430-26-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.